249 related articles for article (PubMed ID: 37924830)
1. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial.
Ramakrishnan S; Jeffers H; Langford-Wiley B; Davies J; Thulborn SJ; Mahdi M; A'Court C; Binnian I; Bright S; Cartwright S; Glover V; Law A; Fox R; Jones A; Davies C; Copping D; Russell RE; Bafadhel M
Lancet Respir Med; 2024 Jan; 12(1):67-77. PubMed ID: 37924830
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.
Sivapalan P; Lapperre TS; Janner J; Laub RR; Moberg M; Bech CS; Eklöf J; Holm FS; Armbruster K; Sivapalan P; Mosbech C; Ali AKM; Seersholm N; Wilcke JT; Brøndum E; Sonne TP; Rønholt F; Andreassen HF; Ulrik CS; Vestbo J; Jensen JS
Lancet Respir Med; 2019 Aug; 7(8):699-709. PubMed ID: 31122894
[TBL] [Abstract][Full Text] [Related]
3. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
5. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
van Velzen P; Ter Riet G; Bresser P; Baars JJ; van den Berg BTJ; van den Berg JWK; Brinkman P; Dagelet JWF; Daniels JMA; Groeneveld-Tjiong DRGL; Jonkers RE; van Kan C; Krouwels FH; Pool K; Rudolphus A; Sterk PJ; Prins JM
Lancet Respir Med; 2017 Jun; 5(6):492-499. PubMed ID: 28483402
[TBL] [Abstract][Full Text] [Related]
6. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
8. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
9. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
Hastie AT; Martinez FJ; Curtis JL; Doerschuk CM; Hansel NN; Christenson S; Putcha N; Ortega VE; Li X; Barr RG; Carretta EE; Couper DJ; Cooper CB; Hoffman EA; Kanner RE; Kleerup E; O'Neal WK; Paine R; Peters SP; Alexis NE; Woodruff PG; Han MK; Meyers DA; Bleecker ER;
Lancet Respir Med; 2017 Dec; 5(12):956-967. PubMed ID: 29146301
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Herath SC; Normansell R; Maisey S; Poole P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009764. PubMed ID: 30376188
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Trials; 2015 Jun; 16():267. PubMed ID: 26058585
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
Fraser A; Poole P
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
[TBL] [Abstract][Full Text] [Related]
13. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease.
Allinson JP; Vlies BH; Brill SE; Law M; Burnside G; Finney LJ; Alves-Moreira L; Donaldson GC; Calverley PMA; Walker PP; Wedzicha JA
Am J Respir Crit Care Med; 2023 Sep; 208(5):549-558. PubMed ID: 37450935
[No Abstract] [Full Text] [Related]
14. Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H; Soe Z; Moe S
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.
Francis NA; Gillespie D; White P; Bates J; Lowe R; Sewell B; Phillips R; Stanton H; Kirby N; Wootton M; Thomas-Jones E; Hood K; Llor C; Cals J; Melbye H; Naik G; Gal M; Fitzsimmons D; Alam MF; Riga E; Cochrane A; Butler CC
Health Technol Assess; 2020 Mar; 24(15):1-108. PubMed ID: 32202490
[TBL] [Abstract][Full Text] [Related]
17. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.
Uzun S; Djamin RS; Kluytmans JA; Mulder PG; van't Veer NE; Ermens AA; Pelle AJ; Hoogsteden HC; Aerts JG; van der Eerden MM
Lancet Respir Med; 2014 May; 2(5):361-8. PubMed ID: 24746000
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
19. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
